ATP2B2 and breast carcinoma: Its role is confirmed in-vitro, since silencing of PMCA2 in MDA-MB-231 breast cancer cells reduces their proliferation, coadiuvate the antiproliferative effect of doxorubicin [49] and increases the necrosis induced by ceramide or ionomycin [46,50].